Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis

被引:7
作者
Hsu, J. C. [1 ,2 ]
Tang, D. H. [3 ]
Lu, C. Y. [4 ,5 ]
机构
[1] Natl Cheng Kung Univ, Sch Pharm, Coll Med, Tainan 70101, Taiwan
[2] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med, Tainan 70101, Taiwan
[3] Univ Arizona, Coll Pharm, Dept Pharmaceut Sci, Tucson, AZ 85721 USA
[4] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA
[5] Harvard Pilgrim Hlth Care Inst, Boston, MA USA
关键词
MEDICINES-PART; 1; QUANTITATIVE APPROACH; NEW-MODEL; SILDENAFIL VIAGRA; SAFETY; EFFICACY; MEN; METAANALYSIS; MANAGEMENT; TADALAFIL;
D O I
10.1111/ijcp.12548
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundErectile dysfunction (ED) is a common male sexual disorder worldwide. Three oral phosphodiesterase type 5 inhibitors (PDE5Is) - sildenafil, tadalafil and vardenafil - are available for treatment of ED. This study quantitatively evaluated the therapeutic efficacy and safety of these medications to assist treatment decision making. MethodsWe used multiple criteria decision analysis (MCDA) to assess the totality of risk-benefit of PDE5Is. We created two models: (i) the overall model included overall improvement in erections' and any adverse events' and (ii) the detailed model included erectile function domain', ability for sexual intercourse', duration of erection last', serious adverse events', headache', flushing' and dyspepsia'. We calculated a synthetic utility for each drug accounting for all of its benefits and risks. ResultsConsidering the overall risk-benefit, vardenafil had the highest synthetic utility among three medications; in the order of synthetic utilities: vardenafil (0.568), tadalafil (0.478) and sildenafil (0.437). However, when specific risk and benefit criteria were assessed, tadalafil had the highest synthetic utility (0.602) according to the conjoint evaluation (synthetic utility for vardenafil is 0.491 and sildenafil is 0.442, respectively). The sensitivity analysis based on the uncertainties of weight on risks of any adverse events (including serious adverse events and headache) suggested our results were robust. ConclusionsThis study provides a useful approach that comprehensively and systematically assesses and compares the risk-benefit of several treatment alternatives. Our study not only rank treatment alternatives by synthetic utilities based on the risk-benefit balance but also compare specific risk and benefit criteria between these medicines. Our results provide valuable evidence that can guide clinicians and patients in making treatment decisions.
引用
收藏
页码:436 / 443
页数:8
相关论文
共 34 条
[1]   Sildenafil (Viagra) is used as a recreational drug in England [J].
Aldridge, J ;
Measham, F .
BRITISH MEDICAL JOURNAL, 1999, 318 (7184) :669-669
[2]   Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction [J].
Aversa, Antonio ;
Bruzziches, Roberto ;
Pili, Marcello ;
Spera, Giovanni .
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (27) :3467-3484
[3]   Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations [J].
Berner, MM ;
Kriston, L ;
Harms, A .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2006, 18 (03) :229-235
[4]   OPTIMAL CALCIUM INTAKE [J].
BILEZIKIAN, JP ;
BAILEY, L ;
ELMER, PJ ;
FAVUS, MJ ;
GO, VLW ;
GOLDRING, SR ;
HOLT, LH ;
INSOGNA, KL ;
KRIMGOLD, B ;
MALLETTE, LE ;
SHAPIRO, JR ;
STJEOR, ST ;
STERN, PH ;
TILLEY, BC ;
YAMAMOTO, ME .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (24) :1942-1948
[5]   Sexual function, dysfunction, and sexual distress in a prospective, population-based sample of mid-aged, Australian-Born women [J].
Dennerstein, Lorraine ;
Guthrie, Janet R. ;
Hayes, Richard D. ;
DeRogatis, Leonard R. ;
Lehert, Philippe .
JOURNAL OF SEXUAL MEDICINE, 2008, 5 (10) :2291-2299
[6]   Multi-Criteria Clinical Decision Support A Primer on the Use of Multiple-Criteria Decision-Making Methods to Promote Evidence-Based, Patient-Centered Healthcare [J].
Dolan, James G. .
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2010, 3 (04) :229-248
[7]   Acute myocardial infarction associated with sildenafil [J].
Feenstra, J ;
van Drie-Pierik, RJHM ;
Laclé, CF ;
Stricker, BHC .
LANCET, 1998, 352 (9132) :957-958
[8]   Multiattribute and single-attribute utility functions for the health utilities index mark 3 system [J].
Feeny, D ;
Furlong, W ;
Torrance, GW ;
Goldsmith, CH ;
Zhu, ZL ;
DePauw, S ;
Denton, M ;
Boyle, M .
MEDICAL CARE, 2002, 40 (02) :113-128
[9]   IMPOTENCE AND ITS MEDICAL AND PSYCHOSOCIAL CORRELATES - RESULTS OF THE MASSACHUSETTS MALE AGING STUDY [J].
FELDMAN, HA ;
GOLDSTEIN, I ;
HATZICHRISTOU, DG ;
KRANE, RJ ;
MCKINLAY, JB .
JOURNAL OF UROLOGY, 1994, 151 (01) :54-61
[10]   A Review of Quantitative Risk-Benefit Methodologies for Assessing Drug Safety and Efficacy-Report of the ISPOR Risk-Benefit Management Working Group [J].
Guo, Jeff J. ;
Pandey, Swapnil ;
Doyle, John ;
Bian, Boyang ;
Lis, Yvonne ;
Raisch, Dennis W. .
VALUE IN HEALTH, 2010, 13 (05) :657-666